Cagrilintide/Selank/Mt2/Dsip/Epithalon/Adipotide/Semax/Ss-31/Retatruti
35 Inquiries
129954-34-3
99%
qingdao
JF
vials
2030-11-28
Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionSELANK Synthetic is a single, non-glycosylated polypeptide chain containing 7 amino acids, having a molecular mass of 751.89 Dalton and a Molecular formula of C33H57N11O9.Basic Info
-
Product Name:
Selank peptide
Other Name:Selank peptide;SelankAcetate;PL14736;L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-proline;L-THREONYL-L-LYSYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYL-L-PROLINE; MONOACETATE;H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH;SLANK;Selank peptid
CAS No.:129954-34-3
Molecular Formula:C33H57N11O9
InChIKeys:JTDTXGMXNXBGBZ-YVHUGQOKSA-N
Molecular Weight:751.87
Exact Mass:751.43407244
EC Number:232-660-2
UNII:TS9JR8EP1G
Categories:
Characteristics-
Density:
1.53±0.1 g/cm3(Predicted)
Melting Point:134-136 °C
PKA:3.43±0.20(Predicted)
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332
-
Location:
Unit D01,3/F., Wong King Industrial Building,No.2 Tai Yau Street, Kowloon
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$50 million-$100 million
-
Total Employees:
51-100
-
Year of Establishment:
2012
-
-
Inquiry History35 Inquiries
Country Product Purchase Quantity Date Posted
United States
Selank 99% Purity 129954-34-3
1 G Jan 23, 2026
Greece
selank
10 MG May 20, 2026
United States
N acetyl selank
500 MG Apr 30, 2026
United States
Selank
100 MG Apr 24, 2026
Italy
Nacetyl selank
1 MT Apr 22, 2026
Oman
Selank
1 G Mar 4, 2026
United States
Selank
30 40' Fcl Oct 14, 2025
United States
selank
100 MG Jul 7, 2026
Netherlands
Selank
10 MT Jun 22, 2026
Netherlands
Selank 20 mg
20 MT Jun 8, 2026
Australia
selank
3 MT Mar 8, 2026
France
Selank
10 MT Feb 28, 2026
Nigeria
retatutride 5mg 10mg 15mg 20mg
100 MG Feb 24, 2026
Canada
FST 344
1 MT Nov 18, 2025
United States
Selank
10 MG Nov 5, 2025
United States
selank
10 MG Nov 3, 2025
United States
Selank
1 G Apr 2, 2025
Norway
98% N-Acetyl Selank Amidate
250 G Dec 17, 2024
Canada
Youngshe 98% Selank N-Acetyl Selank Amidate N-Acetyl Selank
60 G Oct 16, 2024
United States
Selank
20 MT Jan 27, 2024 Post an enquiry for this product